AbstractTo evaluate the effect of vitamin D3 supplementation on cancer mortality in the general population and on prognosis in cancer patients, a systematic review and meta-analysis of randomised, placebo-controlled trials (RCTs) and individual patient data (IPD) was conducted. Overall, 14 RCTs with a total of 104,727 participants (2015 cancer deaths) were identified and 7 RCTs, including …
Category: Oncology
Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer
Importance In a population with significantly increasing rates of individuals with overweight or obesity, understanding the association of obesity with long-term disease risk, such as cancer, is necessary to improve public health.Objective To investigate the association between body mass index (BMI) and gastrointestinal (GI) cancer risk (colorectal cancer [CRC] and noncolorectal GI cancer) in the Prostate, Lung, …
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
BACKGROUNDBetween 1999 and 2009 in the United Kingdom, 82,429 men between 50 and 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed in 2664 men. Of these men, 1643 were enrolled in a trial to evaluate the effectiveness of treatments, with 545 randomly assigned to receive active monitoring, 553 …
Ultra-processed food consumption, cancer risk and cancer mortality: a large-scale prospective analysis within the UK Biobank
Global dietary patterns are increasingly dominated by relatively cheap, highly palatable, and ready-to-eat ultra-processed foods (UPFs). However, prospective evidence is limited on cancer development and mortality in relation to UPF consumption. This study examines associations between UPF consumption and risk of cancer and associated mortality for 34 site-specific cancers in a large cohort of British …
Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study
To the Editor: Alopecia is feared by most patients undergoing systemic anticancer therapy for breast cancer because of its negative impact on quality of life.1 Currently, evidence regarding management of persistent chemotherapy-induced alopecia ( pCIA) and endocrine therapy-induced alopecia (EIA) in patients with breast cancer is lacking.2-4 Although previous studies demonstrated successful use of lowdose …